Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer We performed paired NGS of tumor DNA and plasma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback